Your session is about to expire
← Back to Search
Other
Immunotherapy Combinations for Cancer
Phase 1 & 2
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Available tumor tissue for biomarker analysis
Eastern Cooperative Oncology Group Performance Status (ECOG) status of 0 or 1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights
Study Summary
This trial is testing the safety and effectiveness of a new immunotherapy treatment for various types of cancer.
Who is the study for?
This trial is for adults with certain advanced solid cancers that have spread and can't be removed by surgery. Participants should be relatively healthy (ECOG status of 0 or 1) and have a tumor that can be measured. They must also provide tissue samples for research. People with brain metastases, lung inflammation history, active cancer in the last two years (except some skin cancers), or recent serious neurological issues cannot join.Check my eligibility
What is being tested?
The study tests combinations of immunotherapy drugs: relatlimab with nivolumab and BMS-986205, or relatlimab with nivolumab and ipilimumab. It aims to find out how safe these combinations are and how well they work against different types of advanced tumors in patients who haven't had immunotherapy before as well as those who have.See study design
What are the potential side effects?
Possible side effects include immune-related reactions such as inflammation in various organs like the intestines or liver, skin rash, hormone gland problems (like thyroid dysfunction), fatigue, flu-like symptoms, infusion reactions during drug administration, and potential worsening of underlying conditions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have tumor tissue available for testing.
Select...
I am fully active or can carry out light work.
Select...
My cancer is advanced, cannot be surgically removed, and its size can be measured.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 4 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Disease Control Rate (DCR)
Median Duration of Response (mDOR)
Number of AEs leading to death
+6 moreSecondary outcome measures
Progression-Free Survival (PFS)
Side effects data
From 2023 Phase 1 & 2 trial • 62 Patients • NCT0331061936%
Nausea
36%
Vomiting
36%
Thrombocytopenia
27%
Fatigue
27%
Leukopenia
27%
Anaemia
27%
Hypokalaemia
18%
Hyperbilirubinaemia
18%
Neutropenia
18%
Insomnia
18%
Nasal discomfort
18%
Rash
18%
Hypomagnesaemia
18%
Musculoskeletal chest pain
9%
Encephalopathy
9%
Respiratory syncytial virus infection
9%
Ileus paralytic
9%
Enterocolitis
9%
Pyrexia
9%
Back pain
9%
Cellulitis
9%
Acute kidney injury
9%
Rash maculo-papular
9%
Abdominal pain
9%
Lymphopenia
9%
Pain
9%
Hypogammaglobulinaemia
9%
Cough
9%
Aspartate aminotransferase increased
9%
Hyponatraemia
9%
Headache
9%
Hypophosphataemia
9%
Dysphonia
9%
Oropharyngeal pain
9%
Hiatus hernia
9%
Arthralgia
9%
Nystagmus
9%
Febrile neutropenia
9%
Bloody discharge
9%
Hypertension
9%
Sepsis
9%
Neurotoxicity
9%
Acute respiratory failure
9%
Chapped lips
9%
Alanine aminotransferase increased
9%
Squamous cell carcinoma of skin
9%
Asthenia
9%
Pneumonia
9%
Blood alkaline phosphatase increased
9%
Hypocalcaemia
9%
Muscular weakness
9%
Rhinorrhoea
9%
Abdominal pain upper
9%
Upper respiratory tract infection
9%
Hypertriglyceridaemia
9%
Productive cough
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm A: Cohort 1A JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
Arm C: Cohort 1A JCAR017 Plus CC-220 (Iberdomide) (Post-JCAR017 Infusion)
Arm F: Cohort 1D Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
Arm E: Cohort 1C JCAR017 Plus Relatlimab and/or Nivolumab (Post-JCAR017 Infusion)
Arm F: Cohort 1A Cohort 1A and 1D JCAR017 Plus CC-99282 (Post-JCAR017 Infusion)
Arm B: Cohort 1A JCAR017 Plus CC-122 (Post-JCAR017 Infusion)
Arm D: Cohort 1A JCAR017 Plus Ibrutinib (Pre- and Post-JCAR017 Infusion)
Arm A: Cohort 1B JCAR017 Plus Durvalumab (Post-JCAR017 Infusion)
Trial Design
2Treatment groups
Experimental Treatment
Group I: Arm BExperimental Treatment3 Interventions
Relatlimab + Nivolumab + Ipilimumab
Group II: Arm AExperimental Treatment3 Interventions
Relatlimab + Nivolumab + BMS-986205
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986205
2017
Completed Phase 3
~1200
Ipilimumab
2014
Completed Phase 3
~2620
Relatlimab
2018
Completed Phase 2
~1110
Nivolumab
2014
Completed Phase 3
~4750
Find a Location
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,638 Previous Clinical Trials
4,128,259 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had lung inflammation or scarring before.I haven't had any cancer except for treated skin cancer in the last 2 years.I have tumor tissue available for testing.I am fully active or can carry out light work.My cancer has spread to my brain or is only active there.My cancer is advanced, cannot be surgically removed, and its size can be measured.I haven't had encephalitis, meningitis, or uncontrolled seizures in the last year.
Research Study Groups:
This trial has the following groups:- Group 1: Arm A
- Group 2: Arm B
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is there still availability for participants in this trial?
"Affirmative. The specified clinical trial, which was initially shared on May 30th 2018 and revised most recently on October 24th 2022, is actively searching for 255 individuals to participate at 6 sites across the country according to data provided by clinicaltrials.gov."
Answered by AI
Could you elaborate on what additional research has been conducted concerning Relatlimab?
"At the present time, there are 86 Relatlimab studies in Phase 3 and 766 trials overall. Notably, despite being headquartered in Pittsburgh, Pennsylvania; these medical experiments occur at 42717 different locations across America."
Answered by AI
What medical conditions is Relatlimab commonly employed to treat?
"Relatlimab is usually administered to treat anti-angiogenic therapy. In addition, it has been proven effective for treating neoplasms like melanoma and squamous cell carcinoma that can not be surgically removed."
Answered by AI
How many facilities are offering this clinical trial?
"Currently, this clinical trial is being administered at 6 distinct sites throughout the United States. These include Baltimore, Saint Louis and Cleveland among other metropolitan areas. It would be beneficial for prospective participants to select a nearby site in order to reduce transportation burdens associated with enrolment."
Answered by AI
What is the largest quota of participants in this medical experiment?
"A total of 255 suitable participants are required for this medical trial, which is sponsored by Bristol-Myers Squibb. The research will be conducted at various centres including Sidney Kimmel Comprehensive Cancer Center in Baltimore and Washington University School Of Medicine-Siteman Cancer Centre located in Saint Louis."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger